Exelixis, Inc.
LSE: 0IJO.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Michael Morrissey
- Employees
- 1,147
- Headquarters
- Alameda, United States
- IPO year
- 2018
- Market cap
- $12.4B
- Website
- https://www.exelixis.com
Loading 0IJO…
Loading profile data…Frequently asked questions about 0IJO
What does Exelixis, Inc. (0IJO.L) do?
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ...
Where does 0IJO.L trade?
Exelixis, Inc. (0IJO.L) trades on the London Stock Exchange.
What sector is 0IJO.L in?
Exelixis, Inc. (0IJO.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Exelixis, Inc.?
Michael Morrissey is the chief executive officer of Exelixis, Inc. (0IJO.L).
Where is Exelixis, Inc. headquartered?
Exelixis, Inc. is headquartered in United States.
Does 0IJO.L pay a dividend?
Exelixis, Inc. (0IJO.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0IJO.L go public?
Exelixis, Inc. (0IJO.L) completed its initial public offering in 2018.